SCOPE OF SERVICES
MISSION & VISION
" FDA Approved MammaPrint® Services in Kuwait "
Do you want to predict the chance of surviving breast cancer over the next 10 years ?
Do you want to avoid the trauma and complications of chemotherapy ?
Do you want your physician to give you personalized treatments ?
"This revolutionary MammaPrint® technology will provide valuable information on the likelihood of cancer recurrence in patients with breast cancer.”
Breast cancer isa malignant (cancer) tumor that starts from the cells of the breast. It is found mostly in women, but men can get breast cancer, too. Breast cancer is the most common cancer among women in the United States, other than skin cancer. It is the first leading cause of cancer death in women. The chance of a woman having invasive breast cancer some time during her life is about 1 in 8. The chance of dying from breast cancer is about 1 in 35. Nevertheless, breast cancer death rates are going down. This is probably the result of finding the cancer earlier and providing improved treatment.
MammaPrint® is the first gene test to receive FDA approval and gives clinicians a clear answer for breast cancer prognosis. When breast cancer is diagnosed, the surgeon will try to excise the cancer out the woman’s breast. However, breast cancer can still spread to other body organs months or years later, regardless of surgery. MammaPrint® is a test used to determine the probability of breast cancer spread. The test is performed on a small sample of the cancer tissue when taken during surgery and looks at the gene activity of the cancer cells. The activity of these genes can determine the behavior of the cancer and provides a clear answer on whether the breast cancer is of low or high risk for recurrence within the following 10 years. These results will help doctors determine the best treatment plan.
MAMMAPRINT® AS A PREDICTOR OF THE RISK OF RECURRENCE IN BREAST CANCER PATIENTS:
This gene signature has been developed by The Dutch National Cancer Institute in Amsterdam. MammaPrint® is applicable to all breast cancer cases where the breast cancer measures 5cm or less in maximum dimension and where axillary lymph node involved in metastatic cancer are less than 4 nodes. MammaPrint® classifies breast cancers into two distinct categories: High risk and Low risk.
1. Patients in the low risk category, representing 40% of patients, have a 10-year survival probability of 96%.
2. Patients in the high risk category, representing 60% of patients, have a 10-year survival probability of 50%.
These findings provide Oncologists with information essential for optimizing treatmentmanagement. Patients in the low risk group do not need to have chemotherapy for the control of their breast cancer and their chance of surviving for 10 years is 96%. Therefore, MammaPrint® can provide accurate information on the chances of the patient’s survival for 10 years and also on whether the patient needs to undergo chemotherapy. Hence, chemotherapy is needed for patients in the high risk group.
In February 2007, the U.S. Food and Drug Administration (FDA) has approved MammaPrint® as a test that determines the likelihood of breast cancer returning within 10 years. It is the first and only FDA-cleared molecular test that profiles genetic activity of breast cancer cells. “Clearance of the MammaPrint® test marks a step forward in the initiative to bring molecular-based medicine into current practice.”, said Andrew C. Von Eschenbach, M.D., Commissioner of FDA.
MammaPrint®’s micro-array laboratory test is applicable to fresh samples of primary breast cancer where a small sample of the cancer needs to be taken within one hour of surgical removal. This sample should be transferred into a special RNA preservative solution and then transferred to Amsterdam for analysis. The results are ready within 10 days.
This test is available now in the Middle East, through Gene Profiling Limited and through HSMCC, the exclusive distributors of MammaPrint® in the State of Kuwait.
LOOKING FOR JOB?
Send us your CV
If you are seeking a fulfilling and dynamic career that gives you an opportunity to make a difference and are looking for a great place to work, send your resume or CV to:
Block 1A, Building No. 198